XML 16 R3.htm IDEA: XBRL DOCUMENT v3.24.4
Consolidated Balance Sheets - USD ($)
Sep. 30, 2024
Sep. 30, 2023
Current Assets:    
Cash and cash equivalents $ 3,251,880 $ 26,480,928
Inventory 8,268,766
Prepaid expenses 2,700,000 7,889,506
Total Current Assets 14,220,646 34,370,434
Property and equipment, net 1,432
Operating lease right-of-use asset, net 246,247 454,426
Other Assets:    
Deposits 38,062 38,062
In-process research and development 92,800,000 59,400,000
Goodwill 9,346,796 9,346,796
Total Other Assets 102,184,858 68,784,858
Total Assets 116,651,751 103,611,150
Current Liabilities:    
Accounts payable 4,927,211 2,927,334
License payable 28,400,000
Accrued expenses 17,027 476,300
Accrued compensation 2,229,018 2,156,983
Operating lease liability 241,547 218,380
Total Current Liabilities 35,814,803 5,778,997
Deferred tax liability 6,713,800 6,137,800
Operating lease liability – non current 21,318 262,865
Total Liabilities 42,549,921 12,179,662
Commitments and Contingencies
Stockholders’ Equity:    
Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock - $0.001 par value; 16,000,000 shares authorized; 7,247,243 and 6,354,371 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,247 6,354
Additional paid-in capital 271,440,421 253,056,133
Accumulated deficit (201,370,218) (162,231,379)
Total Citius Pharmaceuticals, Inc. Stockholders’ Equity 70,077,450 90,831,108
Non-controlling interest 4,024,380 600,380
Total Equity 74,101,830 91,431,488
Total Liabilities and Equity $ 116,651,751 $ 103,611,150